Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Commentary|Podcasts|June 26, 2023
Pharmacy Focus: Oncology Edition - A Look Into Psychedelic Medicines for Oncology Care
This month, we have a special crossover episode between Pharmacy Focus: Oncology Edition and the Psychedelic Pharmacy podcast.
Advertisement
This month, we have a special crossover episode between Pharmacy Focus: Oncology Edition and the Psychedelic Pharmacy podcast. Managing Editor Alana Hippensteele spoke with Anthony L. Back, MD, to learn about research into psychedelic medicine in cancer care and what he sees in the future. As psychedelic medicine comes further into cancer care, pharmacists will play a vital role in the interdisciplinary team to screen and evaluate patients for suitability.
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5